Drug Search Results
More Filters [+]

Landogrozumab

Alternative Names: landogrozumab, ly2495655
Latest Update: 2020-09-15
Latest Update Note: News Article

Product Description

Mechanisms of Action: GDF8 Inhibitor

Novel Mechanism: Yes

Modality: Antibody

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Eli Lilly
Company Location: INDIANAPOLIS IN 46285
Company CEO: David A. Ricks
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Landogrozumab

Countries in Clinic: Japan

Active Clinical Trial Count: 1

Highest Development Phases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

JapicCTI-121851

P2

Active

Unknown

None

Recent News Events